Art

J-GLOBAL ID：201702276263812661   Reference number：17A0154289

新規薬剤による治療戦略とケアの実際 悪性リンパ腫 ホジキンリンパ腫

Author (1)： IZUTSU KOJI (虎の門病院 血液内科)
Material： がん看護  (Japanese Journal of Cancer Care)
Volume： 22  Issue： 2  Page： 121-125  Publication year： Feb. 10, 2017 
JST Material Number： L3817A  ISSN： 1342-0569  Document type： Article
Article type： 解説  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： nivolumab ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0154289&from=J-GLOBAL&jstjournalNo=L3817A") }}

JST classification (2)： Blood cell tumors(=neoplasms)  (GK04000M) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Reference (12)：

• Engert A et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363: 640, 2010
• Eich HT et al: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma; final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28: 4199, 2010
• Cheson BD et al: Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma; The Lugano Classification. J Clin Oncol 32: 3059, 2014
• Moccia AA et al: International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. J Clin Oncol 30: 3383, 2012
• Engert A et al: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial); a randomised, open-label, phase 3 non-inferiority trial. Lancet 379: 1791, 2012

Terms in the title (4)： 新規薬剤 ,  治療戦略 ,  悪性リンパ腫 ,  ホジキンリンパ腫